Search

Background: Retinitis pigmentosa (RP) is a group of hereditary retinal dystrophies characterized by progressive degeneration of photoreceptor cells, which results in debilitating visual impairment. This systematic review aims to evaluate the efficacy and safety of emerging treatment modalities for RP, including gene therapy, mesenchymal-cell-based approaches, and supplementary interventions. Methods: A comprehensive search of electronic databases was conducted to identify relevant studies published up to February 2024. Studies reporting outcomes of treatment interventions for RP, including randomized controlled trials, non-randomized studies, and case series, were included. Data extraction and synthesis were performed according to predefined criteria, focusing on assessing the quality of evidence and summarizing key findings. Results: The search yielded 13 studies meeting inclusion criteria, encompassing diverse treatment modalities and study designs. Gene therapy emerged as a promising therapeutic approach, with several studies reporting favorable outcomes regarding visual function preservation and disease stabilization. Mesenchymal-cell-based therapies also demonstrated potential benefits, although evidence remains limited and heterogeneous. Supplementary interventions, including nutritional supplements and neuroprotective agents, exhibited variable efficacy, with conflicting findings across studies. Conclusions: Despite the lack of definitive curative treatments, emerging therapeutic modalities promise to slow disease progression and preserve visual function in individuals with RP. However, substantial gaps in evidence and heterogeneity in study methodologies underscore the need for further research to elucidate optimal treatment strategies, refine patient selection criteria, and enhance long-term outcomes. This systematic review provides a comprehensive synthesis of current evidence and highlights directions for future research to advance the care and management of individuals with RP. [ABSTRACT FROM AUTHOR]

Purpose: To assess the corneal biomechanical properties in normal individuals and patients with keratoconus using the Brillouin optical scanning system (Intelon Optics) (BOSS) and compare them with ultra-high-speed Scheimpflug imaging (Corvis ST; Oculus Optikgeräte GmbH). Methods: Sixty eyes from 60 patients (30 normal and 30 keratoconus) were included in this prospective, single-center, comparative, non-interventional study. Corneal biomechanics were evaluated using the Corvis ST and the BOSS. With the BOSS, each corneal image was acquired three times, measuring 10 locations within an 8-mm diameter. Parameters extracted included mean, maximum, and minimum Brillouin shift. These 10 points were also grouped into superior, central, and inferior regions. BOSS repeatability was assessed using the coefficient of repeatability and coefficient of variation. Furthermore, normal individuals and patients with keratoconus were compared using the Corvis ST and BOSS. Results: The BOSS exhibited good repeatability, with coefficient of repeatability ranging from 0.098 to 0.138 GHz for single points in normal individuals and 0.096 to 0.149 GHz for patients with keratoconus. Statistical analysis revealed significant differences between normal individuals and patients with keratoconus, indicating softer corneas in keratoconus, observed with both the Corvis ST and BOSS. Specifically, the BOSS showed significant differences in mean, inferior, and superior mean, maximum, and minimum Brillouin frequency shift (all P <.05), whereas the Corvis ST displayed highly significant differences in stiffness parameter at first applanation, stress strain index, deformation amplitude ratio, and inverse integrated radius (all P <.001). Conclusions: Corneal biomechanical measurements proved highly repeatable and effectively demonstrated significant differences between normal individuals and patients with keratoconus using both the BOSS and the Corvis ST. [J Refract Surg. 2024;40(8):e569–e578.] [ABSTRACT FROM AUTHOR]

Purpose: To assess the performance of the Camellin-Calossi formula in eyes with prior myopic laser vision correction. Methods: This was a retrospective case series. Patients included had a history of uncomplicated myopic laser vision correction and cataract surgery. The primary outcome measures were cumulative distribution of absolute refractive prediction error, absolute refractive prediction error, and refractive prediction error. These parameters were estimated post-hoc using the Camellin-Calossi, Shammas, Haigis-L, Barrett True-K with or without history, Masket, and Modified Masket formulas and their averages starting from biometric data, clinical records, postoperative refraction, and intraocular lens power implanted. Results: Seventy-seven eyes from 77 patients were included. The Camellin-Calossi, Shammas, Haigis-L, Barrett True-K No History, Masket, Modified Masket, and Barrett True-K formulas showed a median absolute refractive error (interquartile range) of 0.25 (0.53), 0.51 (0.56), 0.44 (0.65), 0.45 (0.59), 0.40 (0.61), 0.60 (0.70), and 0.55 (0.76), respectively. The proportion of eyes with an absolute refractive error of ±0.25, 0.50, 0.75, 1.00, 1.50, and 2.00 diopters (D) for the Camellin-Calossi formula was 54.5%, 72.7%, 85.7%, 92.2%, 98.7%, and 100%, respectively. The cumulative distribution of the Camellin-Calossi formula showed the best qualitative performances when compared to the others. A statistically significant difference was identified with all of the others except the Haigis-L using a threshold of 0.25, with the Shammas, Modified Masket, and Barrett True-K at a threshold of 0.50 D and the Barrett True-K and Modified Masket at a threshold of 1.00 D. Conclusions: The Camellin-Calossi formula is a valid option for intraocular lens power calculation in eyes with prior myopic laser vision correction. [J Refract Surg. 2024;40(3):e156–e163.] [ABSTRACT FROM AUTHOR]